Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview

Entrada Therapeutics

31/07/2026 14:32

Entrada Therapeutics Inc TRDA.OQ TRDA.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2026
The Boston Massachusetts-based  company is expected to report a 78.9% decrease in revenue to $411.43 thousand from $1.95 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Entrada Therapeutics Inc is for a loss of $1.05 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Entrada Therapeutics Inc is $20.00, about 195.4% above its last closing price of $6.77
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.05
-1.04
-0.95
Beat
8.4
Dec. 31 2026
-1.25
-1.15
-0.94
Beat
18.3
Sep. 30 2025
-0.97
-0.94
-1.06
Missed
-12.8​
Jun. 30 2025
-0.86
-0.85
-1.04
Missed
-22.7
​​Mar. 31 2025
-0.79
-0.79
-0.42
Beat
46.8
Dec. 31 2024
-0.67
-0.67
0.03
Beat
104.5​
Sep. 30 2024
-0.71
-0.73
-0.35
Beat
51.9
Jun. 30 2024
0.14
0.15
1.55
Beat
969
This summary was machine generated July 31 at 13:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)